MedImmune And National Institutes Of Health Begin Clinical Testing Of A Live, Attenuated Intranasal Vaccine Against An H5N1 Avian Influenza Virus
submited by kickingbird at Jun, 16, 2006 16:18 PM from Medical News Today
MedImmune, Inc.(Nasdaq: MEDI) announced today that the National Institutes of Health (NIH)has begun enrolling participants in a Phase 1 study of an intranasal H5N1influenza vaccine candidate based on the company´s live, attenuated vaccinetechnology. [click link for full article]
See Also:
Latest news in those days:
- WOAH: Italy - high pathogenicity avian influenza viruses (H5N1)(poultry) 13 days ago
- WOAH: Cambodia - influenza A viruses of high pathogenicity(H5N1) (non-poultry including wild birds) 13 days ago
- China: A human case of avian influenza A(H9N2) reported in Hunan province Mar, 2, 2023
- China: A human case of avian influenza A(H9N2) reported in Sichuan province Feb, 26, 2023
- China: A human case of avian influenza A(H9N2) reported in Hunan province Feb, 26, 2023
[Go Top] [Close Window]
